戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1 ith glioblastoma underwent T1Gd, T2, and 18F-FMISO-11 studies preceded surgical resection or biopsy,
2 8F-FMISO images were scaled to the blood 18F-FMISO activity to create tumor-to-blood ratio (T/B) imag
3 that the distribution of hypoxia seen on 18F-FMISO is correlated spatially and quantitatively with th
4  assessed by 18F-fluoromisonidazole PET (18F-FMISO).
5                                      The 18F-FMISO images were scaled to the blood 18F-FMISO activity
6 imetry were measured in patients during [18F]FMISO and 15O PET imaging.
7 Fluorine 18-labeled fluoromisonidazole ([18F]FMISO), a PET tracer that undergoes irreversible selecti
8                     The organ doses for [18F]FMISO are comparable to those associated with other comm
9 cally different from those reported for [18F]FMISO in the same cell lines (700-1500 ppm).
10 tabolites by 4 h; comparable values for [18F]FMISO were 36% and 57%, respectively.
11 gested that the threshold for increased [18F]FMISO trapping is probably 15 mm Hg or lower.
12 ents following intravenous injection of [18F]FMISO.
13 asma of mice injected with [18F]FETA or [18F]FMISO.
14 nitroimidazole is metabolized less than [18F]FMISO.
15 oxygen dependency of binding similar to [18F]FMISO in vitro and displaying less retention in liver an
16 tudy included 10 patients who underwent [18F]FMISO and 15O PET within 1 to 8 days of severe or modera
17 orts of 10 healthy volunteers underwent [18F]FMISO or 15O PET.
18    Hypoxic volumes were quantified from each FMISO-PET scan following standard techniques.
19                  Hypoxia, indicated by (18)F-FMISO accumulation, was higher in the SaOS-2/Caprin-1 an
20 ed significantly different volumes for (18)F-FMISO and (18)F-FLT (P < 0.001).
21 roducibility of the visual analyses of (18)F-FMISO and (18)F-FLT PET/CT images was demonstrated using
22 e 0.81 for (18)F-FDG and 0.77 for both (18)F-FMISO and (18)F-FLT using the 2-level scale.
23 nterobserver agreement was low for the (18)F-FMISO and (18)F-FLT volume measurements.
24  SUVmax of the aorta could be used for (18)F-FMISO and (18)F-FLT.
25                                        (18)F-FMISO and (18)F-HX4 had similar intermediate tumor uptak
26  were 0.13 and 0.19, respectively, for (18)F-FMISO and 0.2 and 0.3, respectively, for (18)F-FLT.
27  maximum SUV (SUVmax) of the aorta for (18)F-FMISO and 1.3 x SUVmax of the muscle for (18)F-FLT.
28 animals, using the hypoxic cell tracer (18)F-FMISO and the reporter substrate (124)I-FIAU, yielded si
29  administration of 42.1 +/- 3.9 MBq of (18)F-FMISO by tail vein injection.
30                               Variable (18)F-FMISO delivery was observed across lesions, as indicated
31                                        (18)F-FMISO distribution volume deviated from the expected val
32 1/k2, and k3-surrogates for perfusion, (18)F-FMISO distribution volume, and hypoxia-mediated entrapme
33 umor hypoxia (k3), perfusion (K1), and (18)F-FMISO distribution volume.
34 cancer patients underwent 0- to 30-min (18)F-FMISO dPET in a customized immobilization mask, followed
35 0 min, facilitating the translation of (18)F-FMISO dPET into the clinic.
36                             Conclusion:(18)F-FMISO dPET provides the data necessary to generate param
37 udy, pharmacokinetic analysis (PKA) of (18)F-FMISO dynamic PET extended to 3 h after injection is rep
38                                        (18)F-FMISO equilibrates in normoxic tissues but is retained u
39 zole was coadministered with the first (18)F-FMISO injection, and 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2
40                             Conclusion:(18)F-FMISO kinetic modeling reveals a more detailed response
41      These findings support the use of (18)F-FMISO kinetic modeling to more accurately characterize t
42           We derived average values of (18)F-FMISO kinetic parameters for NSCLC lesions as well as fo
43  resulted in a marked reduction in the (18)F-FMISO mean standardized uptake value (SUV(mean)) in appr
44 d to delineate the volume of increased (18)F-FMISO or (18)F-FLT uptake.
45               Two hundred twenty-three (18)F-FMISO patient studies had detectable surrogate blood reg
46 r), CT (of the anatomy), and late-time (18)F-FMISO PET (of the T/B) and parametric images of K(i) (po
47              Simple static analysis of (18)F-FMISO PET captures both the intensity (TBmax) and the sp
48                                        (18)F-FMISO PET could distinguish between different tumor resp
49 a in inflammation using (18)F-FAZA and (18)F-FMISO PET imaging represents a promising new tool for un
50 diagnosed patients underwent a dynamic (18)F-FMISO PET scan before chemotherapy or radiotherapy.
51                                        (18)F-FMISO PET was performed 3 h before and 24 h after treatm
52                         Serial dynamic (18)F-FMISO PET was performed to investigate changes in tumor
53  the present study, static and dynamic (18)F-FMISO PET were performed with mice bearing either U87MG
54                                Dynamic (18)F-FMISO PET with pharmacokinetics modeling, complementary
55 ling further monitored the kinetics of (18)F-FMISO retention to hypoxic sites after treatment.
56  3-min static (18) F-FDG and a dynamic (18)F-FMISO scan lasting 168 +/- 15 min.
57              Patients underwent 20-min (18)F-FMISO scanning during the 90- to 140-min interval after
58 ciated with DFS when adjusting for the (18)F-FMISO status.
59                However, a reduction in (18)F-FMISO SUV(mean) after DMXAA treatment was indicative of
60 ignificant reduction of mean voxelwise (18)F-FMISO TBR, K1, and K1/k2 in both the 2-d and the 7-d gro
61 re analyzed, the observed reduction in (18)F-FMISO uptake after treatment with cediranib may be mista
62  clarify the ambiguity in interpreting (18)F-FMISO uptake and improve the characterization of lesions
63  discrepancy between k3 maps and total (18)F-FMISO uptake and reducing the dynamic range of total (18
64 y an overlap analysis of the volume of (18)F-FMISO uptake and the volumes of the high CBV regions and
65 nd reducing the dynamic range of total (18)F-FMISO uptake for quantifying the degree of hypoxia.
66                                        (18)F-FMISO uptake in NSCLC patients is strongly associated wi
67                                    The (18)F-FMISO uptake on PET/CT was assessed by trained experts.
68     The level and location of hypoxia ((18)F-FMISO uptake, evaluated by tumor-to-blood [T/B] ratio),
69 evertheless exhibited relatively lower (18)F-FMISO uptake.
70            All lesions showed distinct (18)F-FMISO uptake.
71 ibration between the blood and unbound (18)F-FMISO was rapid in all tumors.
72 moral distributions of (124)I-FIAU and (18)F-FMISO were similar, and eGFP, pimonidazole, EF5, and CA9
73 oxia tracers (18)F-fluoromisonidazole ((18)F-FMISO) and (18)F-fluoroazomycinarabinoside ((18)F-FAZA).
74 rfusion with (18)F-fluoromisonidazole ((18)F-FMISO) dynamic PET (dPET) in head and neck cancer.
75 s of (18)F-labeled fluoromisonidazole ((18)F-FMISO) dynamic PET to assist the identification of regio
76              (18)F-fluoromisonidazole ((18)F-FMISO) is the most widely used PET agent for imaging hyp
77  assessed by (18)F-fluoromisonidazole ((18)F-FMISO) PET and conventional and perfusion MRI before sur
78 s to evaluate (18)F-fluromisonidazole ((18)F-FMISO) PET for monitoring the tumor response to the anti
79              (18)F-fluoromisonidazole ((18)F-FMISO) PET is a noninvasive, quantitative imaging techni
80 with dynamic (18)F-fluoromisonidazole ((18)F-FMISO) PET may allow for an improved response assessment
81 s with significant (18)F-misonidazole ((18)F-FMISO) uptake in patients with non-small cell lung carci
82 ((18)F-FDG), (18)F-fluoromisonidazole ((18)F-FMISO), and 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT
83            PET imaging with (18)F-FDG, (18)F-FMISO, and (18)F-fluoride was performed in these mouse m
84 ectively, 0.59 for (18)F-FDG, 0.43 for (18)F-FMISO, and 0.44 for (18)F-FLT using the 5-level scale; t
85                     Ten (18)F-FDG, ten (18)F-FMISO, and ten (18)F-FLT PET/CT examinations were perfor
86  the HT29-9HRE xenograft: (124)I-FIAU, (18)F-FMISO, Hoechst (perfusion), lectin-TRITC (functional blo
87 ed perfusion and therefore delivery of (18)F-FMISO, rather than a reduction in tumor hypoxia.
88                  DFS was longer in the (18)F-FMISO-negative patients (P = 0.004).
89 ng RECIST 1.1 (17/34 responders in the (18)F-FMISO-positive group).
90                                     In (18)F-FMISO-positive patients, the contours of the hypoxic are
91 ncluded, 54 were included, and 34 were (18)F-FMISO-positive, 24 of whom received escalated doses of u
92 adiotracers ((18)F-fluoromisonidazole [(18)F-FMISO], (18)F-flortanidazole [(18)F-HX4], (18)F-fluoroaz
93  ((18)F-FDG, (18)F-fluoromisonidazole [(18)F-FMISO], and (18)F-fluoride) in preclinical mouse models
94                          Fluoromisonidazole (FMISO), labeled with the positron emitter 18F, is a usef
95 ns of [18F]FETA and [18F]fluoromisonidazole (FMISO) at 2 and 4 h postinjection in C3H mice bearing KH
96 lar proliferation, (18)F-fluoromisonidazole (FMISO) for tissue hypoxia, and (11)C-verapamil for P-gly
97 reoperatively with (18)F-fluoromisonidazole (FMISO)-PET and serial gadolinium-enhanced T1- and T2-wei
98 studies to help define the radiation risk of FMISO-PET imaging.
99 ined tumor volume, and the mean intensity on FMISO-PET scaled to the blood activity of the tracer (me

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。